PD-L1 testing and CPS interpretation in squamous cell carcinoma (HNSCC)

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Click to download for more information on PD-L1 Testing and CPS Interpretation in HNSCC

PDF, 1.15 MB

Download this leaflet for more information on PD-L1 testing and CPS scoring in HNSCC.

CPS = Combined Positive Score; HNSCC = Head and Neck Squamous Cell Carcinoma

More information about KEYTRUDA® (pembrolizumab) in first-line head and neck squamous cell carcinoma:

Visit product page

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-PDO-02182 | Date of Preparation: August 2022